RxDoctor Payments Data

Allison Devaux

Family · Murrells Inlet, SCNPI 1326715343

Payments from drug & device makers

$4,787in general payments, 2019–2025

Across 212 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$699
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$693
  • Merck$562
  • Medtronic$470
  • Boston Scientific$410
  • E.r. Squibb & Sons, L.L.C.$334
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$4,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,787 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$41,648
Medicare patients
238
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$94,438
EntrestoSacubitril/Valsartan37$36,480
FarxigaDapagliflozin Propanediol18$20,542
XareltoRivaroxaban24$20,151
BrilintaTicagrelor17$16,263
Bumetanide22$931
Metoprolol Succinate79$726
Olmesartan Medoxomil17$667
Amiodarone Hcl17$623
Spironolactone69$449
Rosuvastatin Calcium54$385
Atorvastatin Calcium46$339
Losartan Potassium37$308
Carvedilol40$299
Hydralazine Hcl20$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$94,43883 claims
AstraZenecaFarxiga, Brilinta$199$36,80535 claims
NovartisEntresto$699$36,48037 claims
Johnson & JohnsonXarelto$53$20,15124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →